|
Colorectal Carcinoma
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the expression of CD93 and the association with two single nucleotide polymorphisms (SNPs), rs2749812 and rs2749817, as possible biomarkers in colorectal cancer (CRC).
|
26008729 |
2015 |
|
Colorectal Carcinoma
|
0.310 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
In the present study, the efficacy and specificity of a <sup>125</sup>I-labeled CD93-specific monoclonal antibody (<sup>125</sup>I-anti-CD93 mAb) in detecting NSCLC xenografts were analyzed, and the association between CD93 expression and <sup>125</sup>I-anti-CD93 mAb uptake by tumors was evaluated.
|
31819775 |
2019 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
These findings demonstrate a key role of CD93 in vascular maturation and organization of the extracellular matrix in tumors, identifying it as a potential target for therapy.
|
29763414 |
2018 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
The C-type lectin domain containing group 14 family members CLEC14A and CD93 are proteins expressed by endothelium and are implicated in tumour angiogenesis.
|
28671670 |
2017 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Blood vessels within intraocular and extraocular neoplasias were used as controls for CD93 expression.
|
27859225 |
2017 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Elevated expression of CD93 promotes angiogenesis and tumor growth in nasopharyngeal carcinoma.
|
27255994 |
2016 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Total CD93 levels were 82% higher (P < 0.001) in tumours compared to matched normal tissues.
|
26008729 |
2015 |
|
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
CD93 expression is functionally required for engraftment of primary human AML LSCs and leukemogenesis, and it regulates LSC self-renewal predominantly by silencing CDKN2B, a major tumor suppressor in AML.
|
26387756 |
2015 |
|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
This effect was associated with increased vascular permeability and decreased vascular perfusion of tumors, indicating reduced vessel functionality in the absence of CD93.
|
26363010 |
2015 |
|
Tumor Angiogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
CD93 (C1q receptor) is reportedly a key regulator of tumor angiogenesis.
|
31819775 |
2019 |
|
Tumor Angiogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis.
|
29763414 |
2018 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
CD93, also known as the complement component C1q receptor (C1qRp), has been reported to promote the progression of some cancer types.
|
27255994 |
2016 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
CD93, also known as the complement component C1q receptor (C1qRp), has been reported to promote the progression of some cancer types.
|
27255994 |
2016 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Cluster of differentiation 93 (CD93) is involved in apoptosis and inflammation and has a suggested role in angiogenesis, and all of which are involved in the development and dissemination of cancer.
|
26008729 |
2015 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Cluster of differentiation 93 (CD93) is involved in apoptosis and inflammation and has a suggested role in angiogenesis, and all of which are involved in the development and dissemination of cancer.
|
26008729 |
2015 |
|
Coronary heart disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Plasma CD93 concentration is a potential novel biomarker for coronary artery disease.
|
21332844 |
2011 |
|
Coronary heart disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We confirmed the associations between four polymorphisms and CHD, the rs1151640 polymorphism in the olfactory receptor family 13 subfamily G member 1 (OR13G1) gene (HR 1.14, 95% CI 1.01-1.28, P = 0.03), the rs11881940 polymorphism in the heterogeneous nuclear ribonucleoprotein U-like 1 (HNRPUL1) gene (HR 1.27, 95% CI 1.07-1.51, P = 0.007), the rs3746731 polymorphism in the complement component 1 q subcomponent receptor 1 (CD93) gene (HR 1.26, 95% CI 1.06-1.49, P = 0.01), and the rs10757274 polymorphism near the cyclin-dependent kinase N2A and N2B (CDKN2A and CDKN2B) genes (HR 1.39, 95% CI 1.15-1.69, P < 0.001).
|
18599554 |
2008 |
|
Diabetic wound
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to evaluate experimentally the effectiveness of applying polycaprolactone (PCL)-gelatin scaffold, with or without rat CD93 hematopoietic stem cells (HSCs), in diabetic wound healing in a rat model.
|
31549396 |
2020 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results revealed the potential applicability of <sup>125</sup>I-anti-CD93 mAb for non-invasive imaging diagnosis of CD93-positive NSCLC.
|
31819775 |
2019 |
|
Asthma
|
0.010 |
Biomarker
|
disease |
BEFREE |
CD93 has received renewed attention as a candidate biomarker of inflammation in various inflammatory and immune-mediated diseases, including asthma.
|
29498549 |
2018 |
|
Encephalomyelitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
We further observed that CD93-deficient (CD93<sup>-/-</sup> ) mice presented a more robust brain and spinal cord inflammation in EAE and ADEAE.
|
29923617 |
2018 |
|
Myelitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
We further observed that CD93-deficient (CD93<sup>-/-</sup> ) mice presented a more robust brain and spinal cord inflammation in EAE and ADEAE.
|
29923617 |
2018 |
|
Inflammatory disease of the central nervous system
|
0.010 |
Biomarker
|
group |
BEFREE |
We propose that CD93 is an important neuro-immune regulator to control central nervous system inflammation.
|
29923617 |
2018 |
|
Malignant Glioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CD93 is a transmembrane receptor that is upregulated in tumor vessels in many cancers, including high-grade glioma.
|
29763414 |
2018 |